The trade war and China’s economic shift made 2018 a tough year for global shipping and will continue to reverberate through the industry, according to the United Nations Conference on Trade and Development.
Regulators want to reduce U.S. dependence on foreign-made pharmaceutical ingredients, as a wave of recalls has raised questions about the safety of the global drug-supply chain.
The decision about whether to keep manufacturing in China or seek other sources must take into account multiple factors, some of them less obvious than others, says Mark Baxa, president and CEO of FerniaCreek LLC.
The region that straddles the Danube in Romania and Bulgaria has made it a bread basket for centuries. But after years of corruption and political upheaval, it’s finally plugged into the world economy thanks to the EU’s open borders and money.
While most business leaders want to avoid a no-deal departure, continued uncertainty is not much better. With the cliff edge looming, and the prospect of another one in three months if the EU grants Parliament’s request for a further delay, collateral damage is mounting.
Chinese officials are willing to start purchasing more U.S. agricultural products as part of the “phase one” trade deal, but it is not likely to reach the $40 billion to $50 billion touted by Trump.
